Drug intelligence / Profile preview

lactobacillus plantarum DSM 9843 + iron

Development stage
Unknown
Lead developer
Probi
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

**lactobacillus plantarum DSM 9843 + iron** is a combination of the probiotic strain *Lactobacillus plantarum* DSM 9843 (commonly known as LP299V) and an iron supplement, used together primarily to improve iron absorption and gastrointestinal tolerability in individuals with iron deficiency or at risk of iron deficiency anemia. LP299V has demonstrated the ability to increase non-heme iron absorption, likely through mechanisms such as the reduction of ferric to bioavailable ferrous iron, enhancing mucin production at the intestinal surface, and modulating the immune response to reduce hepcidin-mediated inhibition of iron transport. This combination aims to address the poor gastrointestinal tolerance often associated with oral iron therapy, improving both iron bioavailability and patient compliance[1][3][5]. The combination has been supported in multiple studies for increasing iron uptake and ferritin levels, especially in populations with increased iron needs, such as athletes and pregnant women, with better GI tolerability compared to iron supplementation alone[1][3][5].

Brand names
LP299V + iron
Other names
lactobacillus plantarum 299v + ironLp299v + iron
02

Targets

HAMP (Hepcidin)

Beyond the preview

Go deeper on lactobacillus plantarum DSM 9843 + iron.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus plantarum DSM 9843 + iron.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call